

# Clinical Features and Virological Findings in Children With Primary Human Herpesvirus 7 Infection

Sadao Suga, MD\*; Tetsushi Yoshikawa, MD\*; Takao Nagai, MD†; and Yoshizo Asano, MD\*

**ABSTRACT.** *Objective.* To elucidate clinical features of patients with primary human herpesvirus 7 (HHV-7) infection and serologic and virologic findings between HHV-7 and human herpesvirus 6 (HHV-6).

*Materials and Methods.* During a 19-month observation period, 71 infants and children (35 boys and 36 girls with a mean age of 14.5 months [range, 1 month to 48 months]) who had acute febrile respiratory illness with or without skin rash were examined clinically and virologically. Heparinized blood samples were used for isolation of HHV-6 and HHV-7 and detection of both virus DNA sequences by a nested polymerase chain reaction amplification. Both virus antibody activities were measured by an indirect immunofluorescent assay.

*Results.* HHV-7 infection was observed in 15 (6 boys and 9 girls with a mean age of 12.9 months [range, 7 months to 27 months]), 1 of 10 with upper respiratory infection and 14 (28%) of 50 with febrile exanthem, whereas HHV-6 infection was in 22 (44%) of the 50. Fever (37.5°C) was observed in all 15, with an average maximum body temperature of 38.7°C (range, 37.6°C to 39.8°C), which persisted for 2.9 days (range, 1 to 5 days). Papular, macular, or maculopapular rash was observed in 14 (93%) of the 15, which appeared on day 2.9 of fever (range, days 2 to 5) on the face, trunk, and extremities and persisted for 2.7 days (range, 1 to 5 days). A convulsive seizure that persisted for a few minutes developed in 1 patient on the first day of elevation of fever. HHV-6 antibody was demonstrated in 13 (87%), and a simultaneous significant increase to HHV-6 antibody titers was observed in 8 (53%) of the 15 during primary HHV-7 infection. HHV-7 and HHV-6 DNAs were almost always detected in mononuclear cells (MNCs) during acute and convalescent phases, whereas HHV-7 DNA was positive in some plasma samples obtained during the acute phase of the disease.

*Conclusions.* Primary HHV-7 infection occurred somewhat later than HHV-6, which was confirmed by the isolation of HHV-7 from blood and/or seroconversion to the virus. Clinical features of a virologically confirmed patient with primary HHV-7 infection were comparable with those of primary HHV-6 infection. Preexisting HHV-6 antibody increased significantly in the half of patients with primary HHV-7 infection. HHV-7 DNA was detected in peripheral blood MNCs and plasma in the acute phase and persisted in MNCs thereafter. *Pediatrics* 1997;99(3). URL: <http://www.pediatrics.org/cgi/content/full/99/3/e4>; human herpesvirus 7, human herpes-

*virus 6, exanthem subitum, roseola infantum, polymerase chain reaction.*

---

ABBREVIATIONS. MNC, mononuclear cell; HHV-7, human herpesvirus 7; HHV-6, human herpesvirus 6; PCR, polymerase chain reaction; bp, base pair; ES, exanthem subitum.

---

Human herpesvirus 7 (HHV-7), isolated from purified and activated CD4+ T lymphocytes from the peripheral blood of a healthy individual in 1990 by Frenkel et al,<sup>1</sup> has been recognized as a new lymphotropic herpesvirus.<sup>2-5</sup> The virus was distinct from the six previously identified human herpesviruses and had limited homology to human cytomegalovirus and human herpesvirus 6 (HHV-6) by both molecular and immunological analyses.<sup>1,2</sup> Healthy adults frequently shed the virus into saliva,<sup>3,4,6</sup> and children are infected at a young age but somewhat later than when infected with HHV-6.<sup>5,7,8</sup> Recent reports have suggested that primary infection with HHV-7 is linked to febrile illness with or without rash that resembles exanthem subitum or roseola infantum.<sup>9-14</sup> However, thus far there is limited information about clinical manifestations of virologically confirmed cases. In the present study, we analyzed 15 patients with primary HHV-7 infection to clarify these points.

## MATERIALS AND METHODS

### Patients

The study was conducted between September 1994 and March 1996 at Fujita Health University Hospital, Akita Hospital, and Nagai Pediatric Clinic. Seventy-one infants and children (35 boys and 36 girls with a mean age of 14.5 months [range, 1 month to 48 months]) who had acute febrile upper and lower respiratory illness with or without skin rash and whose parents agreed to blood sampling more than twice were enrolled in this study. Children with bacterial diseases were excluded from the subjects. Informed consent was obtained from parents of the subjects enrolled in this study after the project was thoroughly explained. A medical history and clinical signs and symptoms were recorded every day by parents for 10 to 14 days on a special form for this project, and we checked the record every 2 to 3 days. The first blood sample was collected within 7 days of the initial visit to our outpatient clinic, and we attempted to collect the convalescent sample 1 week to 2 months later. Children with a history of immune deficiency, those taking cytotoxic or immunosuppressive drugs, and those who had received immunoglobulin were not included in this study.

### Antibody Assays for HHV-7 and HHV-6

Antibody titers to HHV-7 and HHV-6 were measured by an indirect immunofluorescent assay, as described elsewhere.<sup>5,15</sup>

### Virus Isolation and Identification

Isolation of HHV-7 and HHV-6 was performed by cocultivating peripheral blood mononuclear cells (MNCs) from the patient with

From the \*Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Aichi; and †the Nagai Pediatric Clinic, Takamatsu, Kagawa, Japan.

Received for publication Jul 29, 1996; accepted Sep 26, 1996.

Reprint requests to (Y.A.) Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Aichi 470-11 Japan.

PEDIATRICS (ISSN 0031 4005). Copyright © 1997 by the American Academy of Pediatrics.

cord blood MNCs, as described elsewhere.<sup>5,6</sup> Virus isolation was considered positive if the following findings were present: (1) round large cell formation of the cultured cells, and (2) specific immunofluorescence staining with the monoclonal antibody to HHV-7<sup>10</sup> or HHV-6.<sup>16</sup>

### Polymerase Chain Reaction (PCR) for HHV-7 and HHV-6

HHV-7 and HHV-6 DNAs were extracted from peripheral blood MNCs according to procedures reported elsewhere.<sup>12,17</sup> The extracted HHV-6 DNA was amplified by the nested double PCR, as described previously.<sup>17</sup> The outer and inner primers were made following the nucleotide sequences reported elsewhere.<sup>18,19</sup> The primers amplify a DNA fragment of 751 base pairs (bp) of putative large tegument protein gene. The extracted HHV-7 DNA was amplified according to procedures reported elsewhere.<sup>2,12,17</sup> The outer (HV7 and HV8) and inner (HV10 and HV11) primers were made following the nucleotide sequences reported by Berneman et al.<sup>2</sup> These primers amplify a DNA fragment of 124 bp. The specific amplification was confirmed by using proven HHV-7 strains RK<sup>1</sup> and JJ<sup>2</sup> and our own isolates.<sup>5</sup> HHV-6 primers used did not amplify HHV-7 DNA, even at high copy number and vice versa. To avoid false-positive PCR results, disposable syringes and pipettes were used, and all reagents were assayed for the presence of HHV-7 and HHV-6 DNA sequences.

### RESULTS

Blood samples (145; 72 from acute phase and 73 from convalescent phase) were obtained from 71 subjects and used for virus isolation and antibody determination. HHV-7 was isolated from 10 peripheral blood MNCs of 9 patients. Seroconversion or fourfold increase in antibody titers to HHV-7 was observed in 15 of 71. On the other hand, HHV-6 was isolated from 12 of 71, and seroconversion or fourfold increase in antibody titers to HHV-6 was observed in 22 of 71. Thus, HHV-7 infection was confirmed in 15 (6 boys and 9 girls, with a mean age of 12.9 months [range, 7 months to 27 months]), 1 of 10 with upper respiratory infection and 14 (28%) of 50 with febrile exanthem, whereas HHV-6 infection was observed in 22 (44%) of the 50 (Table 1). The results of an isolation of HHV-7 and HHV-6 from peripheral blood MNCs and antibody responses to both viruses in the 15 patients are shown in Table 2. The infection was confirmed by virus isolation in the acute stage and seroconversion to the virus in 8 (cases 1 to 8) of the 15, virus isolation and a 16-fold increase in the antibody titers in 1 (case 9), seroconversion to the virus but no virus isolation from blood in 4 (cases 10 to 13), and a greater than fourfold increase in the antibody titers but no virus isolation in 2 (cases 14 and 15). Case 6 demonstrated seroconversion to both

**TABLE 1.** Clinical Diagnosis and Human Herpesviruses 7 and 6 Involvement in 71 Subjects With Acute Febrile Respiratory Illness\*

Clinical Diagnosis	N	HHV-7	HHV-6
Upper respiratory infection	10	1†	0
Lower respiratory infection	11	0	0
Febrile exanthem	50	14	22

\* HHV-7 was isolated from 10 peripheral blood mononuclear cells obtained at the acute stage of 9 patients, and a seroconversion or  $\geq 4$ -fold increase in antibody titers to HHV-7 was observed in 15 of 71. On the other hand, HHV-6 was isolated from 12 of 71 and a seroconversion or  $\geq 4$ -fold increase in antibody titers to HHV-6 was observed in 22 of 71.

† Diagnosed as croup.

**TABLE 2.** Isolation of Human Herpesviruses 7 and 6 From Blood and Antibody Responses to the Viruses in Children With Primary Human Herpesvirus 7 Infection\*

Case No.	Day of Illness†	Virus Isolation HHV-7	Antibody Response	
			HHV-7	HHV-6
1	3	+	<8	$\geq 1024$
	60	-	256	$\geq 1024$
2	3	+	<8	256
	60	-	128	$\geq 1024$
3	4	+	<8	256
	45	-	64	256
4	5	+	<8	512
	12	-	128	1024
5	30	-	64	512
	2	+	<8	64
6	9	-	64	$\geq 1024$
	4	+	<8	<8
7	7	+	<8	16
	30	-	128	$\geq 1024$
8	60	-	$\geq 256$	$\geq 1024$
	4	+	<8	$\geq 256$
9	13	-	32	$\geq 256$
	2	+	<8	128
10	30	-	128	512
	7	+	8	128
11	60	-	128	256
	4	-	<8	128
12	60	-	128	1024
	3	-	<8	64
13	19	-	32	$\geq 256$
	4	-	<8	<8
14	17	-	32	<8
	4	-	<8	128
15	11	-	32	$\geq 256$
	3	-	8	$\geq 256$
15	12	-	64	$\geq 256$
	4	-	8	64
15	13	-	64	$\geq 256$

\* HHV-6 was not isolated from any sample listed here.

† The first day of elevation of fever was defined as day 0.

viruses, and case 12 showed seroconversion only to HHV-7.

Clinical information is shown in Table 3. Clinical history of exanthem subitum (ES) was documented from 8 (53%) of the 15, and HHV-6 antibody was detected in 13 (87%) of the 15 at the acute stage of primary HHV-7 infection. A simultaneous significant increase (fourfold) in HHV-6 antibody titers was observed in 8 (53%) of the 15 during primary HHV-7 infection. Fever (37.5°C) was observed in all 15, with an average maximum body temperature of 38.7°C (range, 37.6°C to 39.8°C), which persisted for 2.9 days (range, 1 to 5 days). Skin rash was observed in 14 (93%) of the 15. If the first day of elevation of fever (37.5°C) was defined as day 0, the rash appeared on day 2.9 (range, days 2 to 5) and persisted for 2.7 days (range, 1 to 5 days). The rash appeared on only the trunk of 5 patients, on the face, trunk, and extremities of 4, on the trunk and extremities of 3, on the face and trunk of 1, and on the lower limbs of 1. The rash was papular (rubella-like) in 5, macular (measles-like) in 4, maculopapular in 4, and erythema multiforme-like in 1. One patient (case 13) developed a convulsive seizure, which persisted for a few minutes, on the first day of elevated fever.

HHV-7 and HHV-6 DNAs in peripheral blood MNCs and the plasma of 5 of the 15 with primary

**TABLE 3.** Main Clinical Features and History of Exanthem Subitum in Children With Primary Human Herpesvirus 7 Infection

Case No.	Age/Gender	History of Exanthem Subitum	HHV-6 Antibody in the Acute Stage of This Episode	Fever*		Time of Onset	Duration (days)	Skin Rash	
				Duration (days)	Maximum (°C)			Sites	Type
1	10 mo/F	+	+	1	37.6	Day 3	1	Trunk, upper, and lower limbs	Papule
2	10 mo/F	-	+	2	39.3	Day 2	2	Trunk, upper, and lower limbs	Papule
3	9 mo/F	-	+	1	37.8	Day 3	2	Face, trunk, upper, and lower limbs	Papule
4	13 mo/M	+	+	4	39.4	Day 2	5	Face, trunk	Macule
5	15 mo/F	+	+	4	39.3	Day 2	5	Face, trunk upper, and lower limbs	Macule
6	8 mo/M	-	-	5	39.8	Day 5	2	Face, trunk, upper, and lower limbs	Papule
7	15 mo/F	+	+	4	38.5	Day 3	2	Trunk	Macule
8†	7 mo/M	-	+	3	38.6	...	...	...	...
9	19 mo/M	-	+	4	38.3	Day 4	3	Trunk, upper, and lower limbs	Maculopapule
10	21 mo/F	+	+	2	38.4	Day 3	2	Trunk	Maculopapule
11	12 mo/M	+	+	3	37.8	Day 3	2	Trunk	Maculopapule
12	9 mo/F	-	-	2	38.6	Day 3	3	Lower limbs	Erythema-multiforme-like
13	10 mo/M	+	+	2	39.5	Day 2	3	Trunk	Papule
14	8 mo/F	+	+	2	38.7	Day 2	3	Trunk	Macule
15	27 mo/F	-	+	4	39.5	Day 3	3	Face, trunk, upper, and lower limbs	Maculopapule

\* The first day of elevation of fever was defined as day 0.

† Diagnosed as croup.

HHV-7 infection were evaluated by nested PCR (Table 4). HHV-7 DNA was detected in 11 of 13 MNCs obtained between days 2 and 60 but was not detected in two samples of case 6 obtained on days 4 and 7, whereas it was positive in 3 plasma samples obtained during the acute stage of the disease (days 2 to 4). On the other hand, HHV-6 DNA was detected in all MNC samples from the five patients, except for the day 3 sample of case 11, and in only one plasma sample on day 4 from case 6.

### DISCUSSION

In the present study, 15 patients were confirmed as having primary infection with HHV-7, and 14 of

**TABLE 4.** Human Herpesviruses 6 and 7 DNAs in Blood of Children With Primary Human Herpesvirus 7 Infection

Case No.	Day of Illness*	HHV-7 DNA		HHV-6 DNA	
		Mononuclear Cells	Plasma	Mononuclear Cells	Plasma
4	5	++	-	+	-
	12	+	-	+	-
	30	+	-	+	-
6	4	-†	-	+	+
	7	-†	-	+	-
	30	+	-	+	-
8	60	+	-	+	-
	2	++	+	+	-
	30	+	-	+	-
10	4	+	+	+	-
	60	+	-	+	-
11	3	+	+	-	-
	19	+	-	+	-

\* The first day of elevation of fever was defined as day 0.

† HHV-7 was isolated from the same samples.

them had febrile exanthem. The frequency was 28% among 50 with febrile exanthem, comparable with the frequency reported recently by others, ie, 37%<sup>10</sup> and 31%.<sup>13</sup> A larger prospective cohort study will be required to know the precise frequency of primary HHV-7 infection in patients with febrile exanthem and that of febrile exanthem among primary HHV-7 infection in childhood. As suggested elsewhere,<sup>7,9-13,20</sup> the present data also indicate that primary infection with HHV-7 occurs after development of ES, the primary infection with HHV-6, because 54% had a clinical history of ES and 87% had HHV-6 antibody at the acute stage of HHV-7 infection. This is supported further by the data that the mean age of the present 15 cases was 12.9 months, whereas that of 176 ES patients with primary HHV-6 infection was 7.3 months.<sup>21</sup>

Most of the clinical manifestations of primary HHV-7 infection observed in the present study were comparable with those of primary HHV-6 infection or ES. However, the clinical course of typical primary HHV-7 infection may be milder than that of HHV-6 infection. HHV-6-associated ES is characterized by high fever (mean, 39.4°C) lasting 4.1 days, followed by an erythematous and macular or maculopapular rash of 3.8 days' duration,<sup>21</sup> whereas patients with HHV-7-associated febrile exanthem had a maximum fever of 38.7°C lasting 2.9 days, followed by a skin rash of 2.9 days' duration. It is not known whether preexisting immunological memory to HHV-6 would modify the clinical course of primary HHV-7 infection, although cross-reactions of antibodies<sup>2,8,22</sup> and T-cell clones<sup>23</sup> between HHV-6 and HHV-7 were

reported. However, case 12 without immunological memory to HHV-6 had a maximum fever of 38.6°C lasting 2 days, which was milder than that of cases 4, 5, 7 to 9, and 15 with antibody to HHV-6 at the acute stage of the disease. Additional studies on a larger scale are necessary to clarify this point. Of interest is case 6, the patient of which might have simultaneous infections with HHV-7 and HHV-6. He had both viruses or virus DNA in blood from the acute stage of the disease and revealed seroconversion to both viruses, which may explain the highest fever of 39.8°C and the longest febrile period of 5 days of this patient. Case 8 showed clinical features of croup and had fever lasting 3 days without skin rash. It is likely that this patient had simultaneous infection with other viruses<sup>24</sup> such as parainfluenza virus, because most maternal antibodies are lost by 1 year of age. In the present study, 1 patient (7% of the 15) had a convulsive seizure during the febrile phase of the disease, as observed in primary HHV-6 infection.<sup>17,21</sup> It is not known whether HHV-7 invades the central nervous system, although reports of complications linked to primary HHV-7 infection are increasing.<sup>13,25</sup>

As reported elsewhere,<sup>9–11,13</sup> at least 53% of the 15 showed a significant simultaneous rise in antibody titers to HHV-6 during primary HHV-7 infection. This phenomenon will be explained by antigenic cross-reactivities<sup>2,8,22</sup> between both viruses or by reactivation of HHV-6 in a latent form by HHV-7.<sup>26</sup> Alternatively, the simultaneous rise in HHV-6 antibodies could also be explained by nonspecific B-cell response induced by HHV-7 infection. The true mechanism of this phenomenon remains to be answered. Frenkel and Roffman<sup>27</sup> suggested that infection by HHV-7 may have caused febrile exanthem indirectly by reactivating HHV-6 *in vivo* from latency. However, this was unlikely in our study, because HHV-6 was not isolated from blood during acute phase of the primary HHV-7 infection and case 12, the patient of which had no HHV-6 antibody, developed a skin rash. The present study also indicated that a fourfold increase in antibody titers to HHV-6 does not necessarily mean the primary infection is with HHV-6. This observation has implications for the difficulty of laboratory differentiation of febrile exanthem attributable to these two viruses. Moreover, it is important to remind us that enteroviruses and other viral agents should be carefully excluded for differentiating febrile exanthem from HHV-7 and HHV-6 infections.

PCR findings in our study are of interest. Both virus DNA sequences were frequently detected in peripheral blood MNCs obtained at the acute and convalescent stages of the disease. It is likely that the presence of HHV-7 DNA in blood on the acute stage and its persistence thereafter is attributable to the primary infection with HHV-7, as reported in HHV-6 infection.<sup>28–30</sup> Recent reports from other laboratories<sup>31–33</sup> indicated that HHV-7 DNA was detected in 66% to 83% of peripheral blood MNCs of healthy adults. It is also likely that HHV-6 DNA sequences were just persisting in blood after clinical recovery from ES, as suggested elsewhere.<sup>28–30</sup> Alternatively, HHV-6 DNA may be reactivated by the primary

HHV-7 infection,<sup>26</sup> as observed in case 11 in Table 4. Blood sampling before development of the primary HHV-7 infection and quantitative analyses of both virus DNAs by PCR will be required to confirm this point. In cases 8, 10, and 11, HHV-6 DNAs were detected in both peripheral blood MNCs and plasma by PCR. The presence of HHV-7 DNA in plasma of the acute stage may suggest active primary infection with HHV-7, as observed in primary HHV-6 infection.<sup>34</sup> In case 6, it is difficult to interpret data from PCR and virological findings, because HHV-7 was isolated from blood, but the virus DNA was not detected in both MNCs and plasma in the acute phase of the disease. An experimental condition of the methods for detecting virus or virus DNA to compare further may be required. Alternatively, simultaneous infection with both viruses may interfere with replication of each virus, as previously suggested.<sup>24</sup> However, it is likely that this patient had a simultaneous infection with both viruses at this time, based on the temporal relation between HHV-7 viremia, seroconversion to both viruses, and the clinical course of febrile exanthem.

Finally, a consensus is needed on whether the term ES (roseola infantum) should be used only for clinical features by primary infection with HHV-6 or for clinical syndromes featuring febrile exanthem by various infectious agents including HHV-6, HHV-7, enteroviruses, etc.

#### ACKNOWLEDGMENTS

This work was supported in part by the grants from Fujita Health University and Grant-in-Aid for Scientific Research (C), The Ministry of Education, Science and Culture, Japan. Recombinant human interleukin-2 was kindly supplied by Takeda Chemical Industries, Ltd, Osaka, and monoclonal antibodies to HHV-7 and HHV-6 by Drs K. Yamanishi and T. Okuno, the Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.

#### REFERENCES

1. Frenkel N, Schirmer EC, Wyatt LS, et al. Isolation of a new herpesvirus from human CD4 + T cells. *Proc Natl Acad Sci USA*. 1990;87:748–752
2. Berneman ZN, Ablashi DV, Li G, et al. Human herpesvirus 7 is a T-lymphotropic virus and is related to, but significantly different from, human herpesvirus 6 and human cytomegalovirus. *Proc Natl Acad Sci USA*. 1992;89:10552–10556
3. Black JB, Inoue N, Kite-Powell K, Zaki S, Pellett PE. Frequent isolation of human herpesvirus 7 from saliva. *Virus Res*. 1993;29:91–98
4. Hidaka Y, Liu Y, Yamamoto M, et al. Frequent isolation of human herpesvirus 7 from saliva samples. *J Med Virol*. 1993;40:343–346
5. Yoshikawa T, Asano Y, Kobayashi I, et al. Seroepidemiology of human herpesvirus 7 in healthy children and adults in Japan. *J Med Virol*. 1993;41:319–323
6. Wyatt LS, Frenkel N. Human herpesvirus 7 is a constitutive inhabitant of adult human saliva. *J Virol*. 1992;66:3206–3209
7. Wyatt LS, Rodriguez WJ, Balachandran N, Frenkel N. Human herpesvirus 7: antigenic properties and prevalence in children and adults. *J Virol*. 1991;65:6260–6265
8. Clark DA, Freeland JML, Makie PLK, Jarrett RF, Onions DE. Prevalence of antibody to human herpesvirus 7 by age. *J Infect Dis*. 1993;168:251–252
9. Ueda K, Kusuhara K, Okada K, et al. Primary human herpesvirus 7 infection and exanthem subitum. *Pediatr Infect Dis J*. 1994;13:167–168
10. Tanaka K, Kondo T, Torigoe S, Okada S, Mukai T, Yamanishi K. Human herpesvirus 7: another causal agent for roseola (exanthem subitum). *J Pediatr*. 1994;125:1–5
11. Hidaka Y, Okada K, Kusuhara K, Miyazaki C, Tokunaga K, Ueda K. Exanthem subitum and human herpesvirus 7 infection. *Pediatr Infect Dis J*. 1994;11:1010–1011
12. Asano Y, Suga S, Yoshikawa T, Yazaki T, Uchikawa T. Clinical features

- and viral excretion in an infant with primary human herpesvirus 7 infection. *Pediatrics*. 1995;95:187-190
13. Torigoe S, Kumamoto T, Koide W, Taya K, Yamanishi K. Clinical manifestations associated with human herpesvirus 7 infection. *Arch Dis Child*. 1995;72:518-519
  14. Portolani M, Cermelli C, Mirandola P, Di Luca D. Isolation of human herpesvirus 7 from an infant with febrile syndrome. *J Med Virol*. 1995;45:282-283
  15. Suga S, Yoshikawa T, Asano Y, Yazaki T, Ozaki T. Neutralizing antibody assay for human herpesvirus-6. *J Med Virol*. 1990;30:14-19
  16. Okuno T, Asada H, Shiraki K, Takahashi M, Yamanishi K. Analysis of a glycoprotein of human herpesvirus 6 (HHV-6) using monoclonal antibodies. *Virology*. 1990;176:625-628
  17. Suga S, Yoshikawa T, Asano Y, et al. Clinical and virological analyses of 21 infants with exanthem subitum (roseola infantum) and central nervous system complications. *Ann Neurol*. 1993;33:597-603
  18. Aubin JT, Collandre H, Candotti D, et al. Several groups among human herpesvirus 6 strains can be distinguished by Southern blotting and polymerase chain reaction. *J Clin Microbiol*. 1991;29:367-372
  19. Dewhurst S, McIntyre K, Schnabel K, Hall CB. Human herpesvirus 6 (HHV-6) variant B accounts for the majority of symptomatic primary HHV-6 infections in a population of U.S. infants. *J Clin Microbiol*. 1993;31:416-418
  20. Cermelli C, Fabio G, Montorsi M, Sabbatini AM, Portolani M. Prevalence of antibodies to human herpesviruses 6 and 7 in early infancy and age at primary infection. *Microbiologica*. 1996;19:1-8
  21. Asano Y, Yoshikawa T, Suga S, et al. Clinical features of infants with primary human herpesvirus 6 infection (exanthem subitum, roseola infantum). *Pediatrics*. 1994;93:104-108
  22. Foa-Tomasi L, Avitabile E, Ke K, Campadelli-Fiume. Polyvalent and monoclonal antibodies identify major immunogenic proteins specific for human herpesvirus 7-infected cells and have weak cross-reactivity with human herpesvirus 6. *J Gen Virol*. 1994;75:2719-2727
  23. Yasukawa M, Yakushijin Y, Furukawa M, Fujita S. Specificity analysis of human CD4+ T-cell clones directed against human herpesvirus 6 (HHV-6), HHV-7, and human cytomegalovirus. *J Virol*. 1993;67:6259-6264
  24. Suga S, Yoshikawa T, Asano Y, Yazaki T, Yoshida S. Simultaneous infection of human herpesvirus 6 and measles virus in infants. *J Med Virol*. 1990;31:306-311
  25. Hashida T, Komura E, Yoshida M, et al. Hepatitis in association with human herpesvirus 7 infection. *Pediatrics*. 1995;96:783-785
  26. Frenkel N, Wyatt LS. HHV-6 and HHV-7 as exogenous agents in human lymphocytes. *Dev Biol Stand*. 1992;76:259-265
  27. Frenkel N, Roffman E. Human herpesvirus 7. In: Fields BN, Knipe DM, Howley PM, et al, eds. *Fields Virology, 3rd ed*. Philadelphia: Lippincott-Raven Publishers; 1996:2609-2622
  28. Gopal MR, Thomson BJ, Fox J, Tedder RS, Honess RW. Detection by PCR of HHV-6 and EBV DNA in blood and oropharynx of healthy adults and HIV-seropositives. *Lancet*. 1990;336:1598-1599
  29. Kondo K, Kondo T, Okuno T, Takahashi M, Yamanishi K. Latent human herpesvirus 6 infection of human monocytes/macrophages. *J Gen Virol*. 1991;72:1401-1408
  30. Cone RW, Huang MW, Ashley R, Corey L. Human herpesvirus 6 DNA in peripheral blood cells and saliva from immunocompetent individuals. *J Clin Microbiol*. 1993;31:1262-1267
  31. Luca DD, Zorzenon M, Mirandola P, Colle B, Botta GA, Cassai E. Human herpesvirus 6 and human herpesvirus 7 in chronic fatigue syndrome. *J Clin Microbiol*. 1995;33:1660-1661
  32. Wilborn W, Schmidt CA, Lorenz F, et al. Human herpesvirus 7 in blood donors: detection by the polymerase chain reaction. *J Med Virol*. 1995;47:65-69
  33. Kidd IM, Clark DA, Ait-Khaled M, Griffiths PD, Emery VC. Measurement of human herpesvirus 7 load in peripheral blood and saliva of healthy subjects by quantitative polymerase chain reaction. *J Infect Dis*. 1996;174:396-401
  34. Suga S, Yazaki T, Kajita Y, Ozaki T, Asano Y. Detection of human herpesvirus 6 DNAs in samples from several body sites of patients with exanthem subitum and their mothers by polymerase chain reaction assay. *J Med Virol*. 1995;46:52-55

## Clinical Features and Virological Findings in Children With Primary Human Herpesvirus 7 Infection

Sadao Suga, Tetsushi Yoshikawa, Takao Nagai and Yoshizo Asano

*Pediatrics* 1997;99:e4

DOI: 10.1542/peds.99.3.e4

### Updated Information & Services

including high resolution figures, can be found at:  
<http://pediatrics.aappublications.org/content/99/3/e4>

### References

This article cites 33 articles, 13 of which you can access for free at:  
<http://pediatrics.aappublications.org/content/99/3/e4#BIBL>

### Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:  
<http://www.aappublications.org/site/misc/Permissions.xhtml>

### Reprints

Information about ordering reprints can be found online:  
<http://www.aappublications.org/site/misc/reprints.xhtml>

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



# PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

## **Clinical Features and Virological Findings in Children With Primary Human Herpesvirus 7 Infection**

Sadao Suga, Tetsushi Yoshikawa, Takao Nagai and Yoshizo Asano

*Pediatrics* 1997;99:e4

DOI: 10.1542/peds.99.3.e4

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/99/3/e4>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 1997 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

